Diagnose and treat constipation- or diarrhoea-predominant irritable bowel syndrome with confidence

被引：0

作者：

Fenton, Caroline ^{[1
]}

Kang, Connie ^{[1
]}

机构：

[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS & THERAPY PERSPECTIVES | 2022年 / 38卷 / 04期

关键词：

MANAGEMENT; GUIDELINE;

D O I：

10.1007/s40267-022-00906-w

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Irritable bowel syndrome (IBS) is diagnosed based on clinical criteria of regular abdominal pain and disordered defaecation. If first-line treatments such as lifestyle changes fail, patients with diarrhoea-predominant IBS may respond to rifaximin, eluxadoline or, for women, alosetron, if tolerated. For constipation-predominant IBS, options are tegaserod for younger women, and the secretagogues linaclotide, plecanatide, lubiprostone and tenapanor. As IBS is a gut-brain interaction disorder, neuromodulators such as tricyclic antidepressants may help.

引用

页码：171 / 176

页数：6

共 50 条

[21] Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome
Lacy, Brian E.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (08) : 817 - 830
[22] Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome
Leventer, S. M.
Raudibaugh, K.
Frissora, C. L.
Kassem, N.
Keogh, J. C.
Phillips, J.
Mangel, A. W.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (02) : 197 - 206
[23] Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome
Park, J. H.
Rhee, P-L.
Kim, G.
Lee, J. H.
Kim, Y-H.
Kim, J. J.
Rhee, J. C.
Song, S. Y.
NEUROGASTROENTEROLOGY AND MOTILITY, 2006, 18 (07): : 539 - 546
[24] DECREASED LACTOBACILLI IN THE ILEAL MUCOSA-ASSOCIATED MICROBIOTA IN DIARRHOEA-PREDOMINANT IRRITABLE BOWEL SYNDROME
Parkes, G. C.
Petrovska, L.
Woodman, I. J.
Rayment, N. B.
Hudpsith, B. N.
Lomer, M.
Brostoff, J.
Whelan, K.
Sanderson, J. D.
GUT, 2009, 58 : A105 - A106
[25] Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations
Vicario, Maria
Gonzalez-Castro, Ana M.
Martinez, Cristina
Lobo, Beatriz
Pigrau, Marc
Guilarte, Mar
de Torres, Ines
Mosquera, Jose L.
Fortea, Marina
Sevillano-Aguilera, Cesar
Salvo-Romero, Eloisa
Alonso, Carmen
Rodino-Janeiro, Bruno K.
Soderholm, Johan D.
Azpiroz, Fernando
Santos, Javier
GUT, 2015, 64 (09) : 1379 - 1388
[26] Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier
Martinez, Cristina
Lobo, Beatriz
Pigrau, Marc
Ramos, Laura
Maria Gonzalez-Castro, Ana
Alonso, Carmen
Guilarte, Mar
Guila, Meritxell
de Torres, Ines
Azpiroz, Fernando
Santos, Javier
Vicario, Maria
GUT, 2013, 62 (08) : 1160 - 1168
[27] Interplay between gut microbiota and bile acids in diarrhoea-predominant irritable bowel syndrome: a review
Jun-Jie Hou
Wang, Xin
Yu-Ming Wang
Bang-Mao Wang
CRITICAL REVIEWS IN MICROBIOLOGY, 2022, 48 (06) : 696 - 713
[28] Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial
Trifan, Anca
Burta, Ovidiu
Tiuca, Nicoleta
Petrisor, Diana Corina
Lenghel, Augustin
Santos, Javier
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2019, 7 (08) : 1093 - 1101
[29] Involvement of mucosal flora and enterochromaffin cells of the caecum and descending colon in diarrhoea-predominant irritable bowel syndrome
Yang, Jingze
Wang, Peng
Liu, Tong
Lin, Lin
Li, Lixiang
Kou, Guanjun
Zhou, Ruchen
Li, Pan
Li, Yanqing
BMC MICROBIOLOGY, 2021, 21 (01)
[30] Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome
Atkinson, W
Lockhart, S
Whorwell, PJ
Keevil, B
Houghton, LA
GASTROENTEROLOGY, 2006, 130 (01) : 34 - 43

← 1 2 3 4 5 →